

BrainChild Bio Announces Launch to Provide Transformational Therapies for Tumors in Children

Client News

December 5, 2023

Gunderson Dettmer represented client BrainChild Bio, a kids-first clinical-stage biotechnology company, in its launch by Seattle Children's. BrainChild Bio is advancing a next-generation CAR T-cell therapy platform that weaves together synthetic technologies, including multiplex targeting and enhanced potency controls, to provide transformational therapies for tumors of the central nervous system in children. BrainChild Bio will be granted an exclusive license to novel CAR T-cell technology for CNS tumors developed at Seattle Children's. These developments will build upon the pioneering CAR T-cell therapy and clinical translational work of Michael Jensen, M.D. and his team at Seattle Children's Therapeutics.

Since 2012, Seattle Children's Therapeutics has designed, manufactured and launched a robust portfolio of immunotherapy clinical trials for leukemia and lymphoma, brain tumors, and solid tumors, enrolling more than 500 patients. The launch of BrainChild Bio is a natural progression of Seattle Children's Therapeutics' goal to expand access to potentially life-changing therapies through collaborations with biotech companies.

In the [announcement of the launch](#), BrainChild Bio Founder and Chief Scientific Officer Michael Jensen said, "BrainChild Bio is founded with a mission to bring the best ideas forward to push the bounds of scientific discovery in service of children with cancer. For far too long, children have been deprioritized for commercialized medicines, and families have been left without options. We are steadfast in our

commitment to cracking the code of harnessing CAR T-cell technology in CNS tumors and we are uniquely positioned to do so.”

The Gunderson Dettmer deal team was led by Tim Ehrlich and included Jen Lichtman and Beatrice Igne-Bianchi.

Companies

BrainChild

Seattle Children's Therapeutics

Related People



Timothy H. Ehrlich

PARTNER

P +1 617 648 9399

Related Services

Life Sciences Licensing & Strategic Partnering

Private & Public Companies

Featured Insights

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in “Where the legal battle stands around copyright and AI training”

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding